Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 28.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here is how Arbutus Biopharma (ABUS) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript February 29, 2024 Arbutus Biopharma Corporation reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. ABUS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and […]